Investors & Media

Phase 2 study results of Ionis’ novel antisense treatment for hereditary angioedema to be presented at ACAAI annual meeting

– Positive Phase 2 study results demonstrate significant efficacy of donidalorsen (formerly IONIS-PKK-LRx) in the reduction of hereditary angioedema attacks – Based on the results of the Phase 2 study, Ionis plans to initiate a Phase 3 program of donidalorsen in people with HAE CARLSBAD, Calif.

Read more
You are now leaving to visit